Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 174

1.

Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.

Sonpavde G, Agarwal N, Pond GR, Nagy RJ, Nussenzveig RH, Hahn AW, Sartor O, Gourdin TS, Nandagopal L, Ledet EM, Naik G, Armstrong AJ, Wang J, Bilen MA, Gupta S, Grivas P, Pal SK, Lanman RB, Talasaz A, Lilly MB.

Cancer. 2019 Jan 8. doi: 10.1002/cncr.31959. [Epub ahead of print]

PMID:
30620391
2.

Assessing the Prognostic Value of the Automated Bone Scan Index for Prostate Cancer-Reply.

Armstrong AJ, Nordle O, Morris M.

JAMA Oncol. 2018 Dec 13. doi: 10.1001/jamaoncol.2018.5874. [Epub ahead of print] No abstract available.

PMID:
30543364
3.

An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men.

Armstrong AJS, Shaffer M, Nusbacher NM, Griesmer C, Fiorillo S, Schneider JM, Preston Neff C, Li SX, Fontenot AP, Campbell T, Palmer BE, Lozupone CA.

Microbiome. 2018 Nov 5;6(1):198. doi: 10.1186/s40168-018-0580-7.

4.

Updates in advanced prostate cancer 2018.

Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):449-450. doi: 10.1038/s41391-018-0100-7. Epub 2018 Oct 2. No abstract available.

PMID:
30279577
5.

Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas.

Jolly MK, Somarelli JA, Sheth M, Biddle A, Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A, Levine H.

Pharmacol Ther. 2018 Sep 28. pii: S0163-7258(18)30172-4. doi: 10.1016/j.pharmthera.2018.09.007. [Epub ahead of print] Review.

PMID:
30268772
6.

A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST.

Clin Cancer Res. 2019 Jan 1;25(1):43-51. doi: 10.1158/1078-0432.CCR-18-1912. Epub 2018 Sep 19.

PMID:
30232224
7.

Precision Medicine Approaches When Prostate Cancer Akts Up.

Zhang T, George DJ, Armstrong AJ.

Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-2491. [Epub ahead of print]

PMID:
30206162
8.

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Armstrong AJ, Lin P, Higano CS, Sternberg CN, Sonpavde G, Tombal B, Templeton AJ, Fizazi K, Phung D, Wong EK, Krivoshik A, Beer TM.

Ann Oncol. 2018 Nov 1;29(11):2200-2207. doi: 10.1093/annonc/mdy406.

PMID:
30202945
9.

Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation.

Wu M, Huang PH, Zhang R, Mao Z, Chen C, Kemeny G, Li P, Lee AV, Gyanchandani R, Armstrong AJ, Dao M, Suresh S, Huang TJ.

Small. 2018 Aug;14(32):e1801131. doi: 10.1002/smll.201801131. Epub 2018 Jul 3.

PMID:
29968402
10.

Is Ki67 prognostic for aggressive prostate cancer? A multicenter real-world study.

Fantony JJ, Howard LE, Csizmadi I, Armstrong AJ, Lark AL, Galet C, Aronson WJ, Freedland SJ.

Biomark Med. 2018 Jul;12(7):727-736. doi: 10.2217/bmm-2017-0322. Epub 2018 Jun 15.

PMID:
29902938
11.

Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?

Brown LC, Sonpavde G, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):419-430. doi: 10.1038/s41391-018-0049-6. Epub 2018 Jun 1.

PMID:
29858595
12.

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Armstrong AJ, Anand A, Edenbrandt L, Bondesson E, Bjartell A, Widmark A, Sternberg CN, Pili R, Tuvesson H, Nordle Ö, Carducci MA, Morris MJ.

JAMA Oncol. 2018 Jul 1;4(7):944-951. doi: 10.1001/jamaoncol.2018.1093.

PMID:
29799999
13.

Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.

Rathkopf DE, Beer TM, Loriot Y, Higano CS, Armstrong AJ, Sternberg CN, de Bono JS, Tombal B, Parli T, Bhattacharya S, Phung, Krivoshik A, Scher HI, Morris MJ.

JAMA Oncol. 2018 May 1;4(5):694-701. doi: 10.1001/jamaoncol.2017.5808.

14.

Factors Influencing Functional Outcomes and Return-to-Work After Amputation: A Review of the Literature.

Darter BJ, Hawley CE, Armstrong AJ, Avellone L, Wehman P.

J Occup Rehabil. 2018 Dec;28(4):656-665. doi: 10.1007/s10926-018-9757-y. Review.

PMID:
29397480
15.

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.

Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T.

J Immunother Cancer. 2018 Jan 25;6(1):4. doi: 10.1186/s40425-018-0314-1. Review.

16.

Clinical utility of non-EpCAM based circulating tumor cell assays.

Austin RG, Huang TJ, Wu M, Armstrong AJ, Zhang T.

Adv Drug Deliv Rev. 2018 Feb 1;125:132-142. doi: 10.1016/j.addr.2018.01.013. Epub 2018 Jan 31. Review.

PMID:
29366804
17.

Effect of Prophylactic Calcitriol Administration on Serum Ionized Calcium Concentrations after Parathyroidectomy: 78 Cases (2005-2015).

Armstrong AJ, Hauptman JG, Stanley BJ, Klocke E, Burneko M, Holt DE, Runge JJ, Rubin JA.

J Vet Intern Med. 2018 Jan;32(1):99-106. doi: 10.1111/jvim.15028. Epub 2017 Dec 27.

18.

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.

McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Sep;21(3):306-318. doi: 10.1038/s41391-017-0014-9. Epub 2017 Dec 20. Review.

PMID:
29263421
19.

Platinum sensitivity in metastatic prostate cancer: does histology matter?

Humeniuk MS, Gupta RT, Healy P, McNamara M, Ramalingam S, Harrison M, George D, Zhang T, Wu Y, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):92-99. doi: 10.1038/s41391-017-0017-6. Epub 2017 Dec 11.

PMID:
29230006
20.

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI.

Ann Oncol. 2018 Jan 1;29(1):23-25. doi: 10.1093/annonc/mdx648. No abstract available.

21.

Standardization of Laparoscopic Operative Reporting: Improving Gynaecological Surgeon Communication.

Pope RJ, Abdelbadee AY, Armstrong AJ, Ganesh PR, Bedaiwy MA, Zanotti KM.

J Obstet Gynaecol Can. 2018 Mar;40(3):304-309. doi: 10.1016/j.jogc.2017.07.023. Epub 2017 Oct 12.

PMID:
29032066
22.

The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.

Zhang T, Armstrong AJ.

J Clin Oncol. 2017 Oct 1;35(28):3175-3177. doi: 10.1200/JCO.2017.74.7931. Epub 2017 Aug 15. No abstract available.

PMID:
28809609
23.

Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.

Zhu J, Tucker M, Wang E, Grossman JS, Armstrong AJ, George DJ, Zhang T.

Clin Genitourin Cancer. 2017 Dec;15(6):e1137-e1141. doi: 10.1016/j.clgc.2017.07.005. Epub 2017 Jul 14. No abstract available.

PMID:
28780018
24.

Microbiome and metabolome data integration provides insight into health and disease.

Shaffer M, Armstrong AJS, Phelan VV, Reisdorph N, Lozupone CA.

Transl Res. 2017 Nov;189:51-64. doi: 10.1016/j.trsl.2017.07.001. Epub 2017 Jul 14. Review.

25.

Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo.

Taplin ME, Armstrong AJ, Lin P, Krivoshik A, Phung, Parli T, Tombal B, Beer TM.

J Urol. 2017 Dec;198(6):1324-1332. doi: 10.1016/j.juro.2017.07.071. Epub 2017 Jul 20.

PMID:
28736322
26.

Achieving assessor accuracy on the International Standards for Neurological Classification of Spinal Cord Injury.

Armstrong AJ, Clark JM, Ho DT, Payne CJ, Nolan S, Goodes LM, Harvey LA, Marshall R, Galea MP, Dunlop SA.

Spinal Cord. 2017 Nov;55(11):994-1001. doi: 10.1038/sc.2017.67. Epub 2017 Jun 20.

PMID:
28631745
27.

Exploiting DNA damage without repair: The activity of platinum chemotherapy in BRCA-mutated prostate cancers.

Humeniuk MS, Zhang T, Armstrong AJ.

Cancer. 2017 Sep 15;123(18):3441-3444. doi: 10.1002/cncr.30806. Epub 2017 Jun 13. No abstract available.

28.

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Armstrong AJ, Halabi S, Healy P, Alumkal JJ, Winters C, Kephart J, Bitting RL, Hobbs C, Soleau CF, Beer TM, Slottke R, Mundy K, Yu EY, George DJ.

Eur J Cancer. 2017 Aug;81:228-236. doi: 10.1016/j.ejca.2017.02.030. Epub 2017 May 11.

PMID:
28502694
29.

RECISTing the Temptation to Prematurely Stop Nivolumab.

Humeniuk MS, Armstrong AJ.

Eur Urol. 2017 Sep;72(3):377-378. doi: 10.1016/j.eururo.2017.04.021. Epub 2017 Apr 25. No abstract available.

PMID:
28454661
30.

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells.

Ware KE, Gilja S, Xu S, Shetler S, Jolly MK, Wang X, Bartholf Dewitt S, Hish AJ, Jordan S, Eward W, Levine H, Armstrong AJ, Somarelli JA.

J Vis Exp. 2017 Apr 7;(122). doi: 10.3791/55520.

31.

Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.

Armstrong AJ.

Clin Adv Hematol Oncol. 2017 Mar;15(3):184-188. No abstract available.

PMID:
28398272
32.

Drug development in prostate cancer: time to embrace RECIST?

Sonpavde G, Armstrong AJ.

Lancet Oncol. 2017 Apr;18(4):419-421. doi: 10.1016/S1470-2045(17)30149-3. Epub 2017 Mar 8. No abstract available.

PMID:
28283283
33.

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.

Armstrong AJ, Saad F, Phung, Dmuchowski C, Shore ND, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J.

Cancer. 2017 Jun 15;123(12):2303-2311. doi: 10.1002/cncr.30587. Epub 2017 Feb 7.

34.

Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer.

Ramalingam S, Humeniuk MS, Hu R, Rasmussen J, Healy P, Wu Y, Harrison MR, Armstrong AJ, George DJ, Zhang T.

Urol Oncol. 2017 Jun;35(6):418-424. doi: 10.1016/j.urolonc.2016.12.016. Epub 2017 Jan 23.

PMID:
28126272
35.

Reply to M.A.N. Şendur et al and J. Michels.

Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung, Higano CS.

J Clin Oncol. 2017 Jan;35(1):123. Epub 2016 Oct 31. No abstract available.

PMID:
28034066
36.

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial.

Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D.

Prostate. 2017 Mar;77(4):385-395. doi: 10.1002/pros.23277. Epub 2016 Nov 16.

37.

Predictive medicine: Using circulating biomarkers to guide management of patients with genitourinary cancers.

Armstrong AJ.

Urol Oncol. 2016 Nov;34(11):488-489. doi: 10.1016/j.urolonc.2016.09.009. Epub 2016 Oct 26. No abstract available.

PMID:
27793467
38.

Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.

Ramalingam S, Eisenberg A, Foo WC, Freedman J, Armstrong AJ, Moss LG, Harrison MR.

Int J Urol. 2016 Dec;23(12):1038-1041. doi: 10.1111/iju.13225. Epub 2016 Oct 21.

39.

Magnetic separation of acoustically focused cancer cells from blood for magnetographic templating and analysis.

Shields Iv CW, Wang JL, Ohiri KA, Essoyan ED, Yellen BB, Armstrong AJ, López GP.

Lab Chip. 2016 Sep 21;16(19):3833-3844.

PMID:
27713979
40.

Whole Genomic Copy Number Alterations in Circulating Tumor Cells from Men with Abiraterone or Enzalutamide-Resistant Metastatic Castration-Resistant Prostate Cancer.

Gupta S, Li J, Kemeny G, Bitting RL, Beaver J, Somarelli JA, Ware KE, Gregory S, Armstrong AJ.

Clin Cancer Res. 2017 Mar 1;23(5):1346-1357. doi: 10.1158/1078-0432.CCR-16-1211. Epub 2016 Sep 6.

41.

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.

Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B.

Eur Urol. 2017 Feb;71(2):151-154. doi: 10.1016/j.eururo.2016.07.032. Epub 2016 Jul 28.

42.

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer.

Ware KE, Somarelli JA, Schaeffer D, Li J, Zhang T, Park S, Patierno SR, Freedman J, Foo WC, Garcia-Blanco MA, Armstrong AJ.

Oncotarget. 2016 Aug 2;7(31):50507-50521. doi: 10.18632/oncotarget.10476.

43.

Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2.

Somarelli JA, Shetler S, Jolly MK, Wang X, Bartholf Dewitt S, Hish AJ, Gilja S, Eward WC, Ware KE, Levine H, Armstrong AJ, Garcia-Blanco MA.

Mol Cell Biol. 2016 Sep 12;36(19):2503-13. doi: 10.1128/MCB.00373-16. Print 2016 Oct 1.

45.

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Antonarakis ES, Armstrong AJ, Dehm SM, Luo J.

Prostate Cancer Prostatic Dis. 2016 Sep;19(3):231-41. doi: 10.1038/pcan.2016.17. Epub 2016 May 17. Review.

46.

Prey Density Threshold and Tidal Influence on Reef Manta Ray Foraging at an Aggregation Site on the Great Barrier Reef.

Armstrong AO, Armstrong AJ, Jaine FR, Couturier LI, Fiora K, Uribe-Palomino J, Weeks SJ, Townsend KA, Bennett MB, Richardson AJ.

PLoS One. 2016 May 4;11(5):e0153393. doi: 10.1371/journal.pone.0153393. eCollection 2016.

47.

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

Evans CP, Higano CS, Keane T, Andriole G, Saad F, Iversen P, Miller K, Kim CS, Kimura G, Armstrong AJ, Sternberg CN, Loriot Y, de Bono J, Noonberg SB, Mansbach H, Bhattacharya S, Perabo F, Beer TM, Tombal B.

Eur Urol. 2016 Oct;70(4):675-683. doi: 10.1016/j.eururo.2016.03.017. Epub 2016 Mar 19.

PMID:
27006332
48.

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ.

J Clin Oncol. 2016 May 10;34(14):1652-9. doi: 10.1200/JCO.2015.65.7270. Epub 2016 Mar 7.

49.

Development of a Novel c-MET-Based CTC Detection Platform.

Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ.

Mol Cancer Res. 2016 Jun;14(6):539-47. doi: 10.1158/1541-7786.MCR-16-0011. Epub 2016 Mar 7.

50.

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol. 2016 Apr 20;34(12):1402-18. doi: 10.1200/JCO.2015.64.2702. Epub 2016 Feb 22.

Supplemental Content

Loading ...
Support Center